-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, KwJ150dTRaHo5U8gGp2TlFbz/zUsAa73aoLbnCqFY/HbHkTRwFBINtYYYQuLHwvu htNcTZARzcnDXu7j8lg7OQ== 0000849043-04-000093.txt : 20041005 0000849043-04-000093.hdr.sgml : 20041005 20041004173924 ACCESSION NUMBER: 0000849043-04-000093 CONFORMED SUBMISSION TYPE: S-8 PUBLIC DOCUMENT COUNT: 3 FILED AS OF DATE: 20041005 DATE AS OF CHANGE: 20041004 EFFECTIVENESS DATE: 20041005 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NEUROGEN CORP CENTRAL INDEX KEY: 0000849043 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 222845714 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: S-8 SEC ACT: 1933 Act SEC FILE NUMBER: 333-119525 FILM NUMBER: 041063618 BUSINESS ADDRESS: STREET 1: 35 NORTHEAST INDUSTRIAL RD CITY: BRANFORD STATE: CT ZIP: 06405 BUSINESS PHONE: 2034888201 MAIL ADDRESS: STREET 1: 35 NORTHEAST INDUSTRIAL RD CITY: BRANFORD STATE: CT ZIP: 06405 S-8 1 fs8100404stock2001.htm Neurogen Corporation Form S-8

As filed with the Securities and Exchange Commission on October 4, 2004

Registration No. 333-


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
__________________

FORM S-8

REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
__________________

NEUROGEN CORPORATION
(Exact name of registrant as specified in its charter)

Delaware

 

22-2845714

(State or other jurisdiction
of incorporation or organization)

 

(I.R.S. Employer Identification No.)

 

 

 

35 Northeast Industrial Road
Branford, Connecticut

 


06405

(Address of Principal Executive Offices)

 

(Zip Code)

 

Amended and Restated Neurogen Corporation 2001 Stock Option Plan
(Full title of the plan)

Stephen R. Davis, Esq.
Executive Vice President and Chief Business Officer
Neurogen Corporation
35 Northeast Industrial Road
Branford, Connecticut 06405
(Name and address of agent for service)

(203) 488-8201
(Telephone number, including area code, of agent for service)

Copies to:

Robert B. Williams, Esq.
Milbank, Tweed , Hadley & McCloy LLP
1 Chase Manhattan Plaza
New York, New York 10005
(212) 530-5000

 

CALCULATION OF REGISTRATION FEE

 

Title of Securities
to be Registered

 

Amount to be Registered (1)

Proposed
Maximum
Offering Price
Per Share (1)(2)

Proposed
Maximum
Aggregate
Offering Price
(1)(2)


Amount of Registration Fee

Common Stock, par value $.025
per share (1)


1,500,000


$ 6.225


$ 9,337,500


$ 1,183.06

(1) This Registration Statement shall also cover any additional shares of common stock that become issuable under the Amended and Restated Neurogen Corporation 2001 Stock Option Plan, as amended, by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without the receipt of consideration that results in an increase in the number of the outstanding shares of the Registrant’s common stock.

(2) Estimated in accordance with Rule 457(h) under the Securities Act of 1933, as amended, solely for the purpose of calculating the registration fee, based upon the average of the high and low sales prices of the Registrant’s common stock as reported on the Nasdaq National Market on September 27, 2004.


PART II

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

ITEM 3. INCORPORATION OF DOCUMENTS BY REFERENCE

This Registration Statement on Form S-8 is being filed for the purpose of registering an additional 1,500,000 shares of our common stock that may be issued pursuant to our Amended and Restated Neurogen Corporation 2001 Stock Option Plan, as amended (the “Plan”). A total of 2,000,000 shares of our common stock issuable under the Plan have been previously registered pursuant to our Registration Statement on Form S-8 filed with the Securities and Exchange Commission on November 16, 2001 (Registration No. 333-73576). In accordance with the provisions of General Instruction E to Form S-8, the information contained therein is incorporated herein by reference.

ITEM 8. EXHIBITS

Exhibit
Number

Description

   

4.1

Amended and Restated Neurogen Corporation 2001 Stock Option Plan, as amended (incorporated by reference to Appendix D of the Registrant’s Definitive Proxy Statement on Schedule 14A (File No. 000-18311) filed on July 12, 2004 ).

   

5.1

Opinion of Milbank, Tweed , Hadley & McCloy LLP, Counsel to Registrant.

   

23.1

Consent of Milbank, Tweed , Hadley & McCloy LLP (contained in Exhibit 5.1).

   

23.2

Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm.

   

24.1

Powers of Attorney (included on signature page).

 

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Branford , State of Connecticut , on October 4, 2004.

  NEUROGEN CORPORATION
   
  By: /s/ STEPHEN R. DAVIS
    Stephen R. Davis
   

Executive Vice President and Chief Business Officer

     

 

POWER OF ATTORNEY

KNOW ALL YE PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints William H. Koster and Stephen R. Davis, and each of them, his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as the undersigned might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitute or substit utes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated:

SIGNATURE

TITLE

DATE

 

 

 

/s/ FRANK C. CARLUCCI
Frank C. Carlucci

Chairman of the Board and
Director

October 4, 2004

     

/s/ WILLIAM H. KOSTER
William H. Koster
(Principal Executive Officer)

President, Chief Executive Officer
and Director

October 4, 2004

     

/s/ STEPHEN R. DAVIS
Stephen R. Davis
(Principal Financial and
Accounting Officer)

Executive Vice President, Chief
Business Officer and Director

October 4, 2004

     

/s/ FELIX J. BAKER
Felix J. Baker

Director

October 4, 2004

     

/s/ JULIAN C. BAKER
Julian C. Baker

Director

October 4, 2004

     

/s/ ERAN BROSHY
Eran Broshy

Director

October 4, 2004

     

/s/ ROBERT N. BUTLER
Robert N. Butler

Director

October 4, 2004

     

/s/ STEWART HEN
Stewart Hen

Director

October 4, 2004

     

/s/ JONATHAN S. LEFF
Jonathan S. Leff

Director

October 4, 2004

     

/s/ MARK NOVITCH
Mark Novitch

Director

October 4, 2004

     

/s/ CRAIG SAXTON
Craig Saxton

Director

October 4, 2004

     

/s/ JOHN SIMON
John Simon

Director

October 4, 2004

     

/s/ SUZANNE H. WOOLSEY
Suzanne H. Woolsey

Director

October 4, 2004


INDEX TO EXHIBITS

Exhibit
Number

Description of Document

   

4.1

Amended and Restated Neurogen Corporation 2001 Stock Option Plan, as amended (incorporated by reference to Appendix D of the Registrant’s Definitive Proxy Statement on Schedule 14A (File No. 000-18311) filed on July 12, 2004).

   

5.1

Opinion of Milbank, Tweed , Hadley & McCloy LLP, Counsel to Registrant.

   

23.1

Consent of Milbank, Tweed , Hadley & McCloy LLP (contained in Exhibit 5.1).

   

23.2

Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm.

   

24.1

Powers of Attorney (included on signature page).

 

 

EX-23 2 fs8100404exhibit232.htm Neurogen Corporation Form S-8 Exhibit 23.2

Exhibit 23.2

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM


We hereby consent to the incorporation by reference in this Registration Statement on Form S-8 of our report dated March 5, 2004, relating to the financial statements of Neurogen Corporation, which appears in Neurogen Corporation's Annual Report on Form 10-K for the year ended December 31, 2003.


/s/ PRICEWATERHOUSECOOPERS LLP

Hartford, Connecticut
October 4, 2004

EX-5 3 fs8100404exhibit51.htm Neurogen Corporation Form S-8 Exhibit 5.1

Exhibit 5.1

October 4, 2004

Neurogen Corporation
35 Northeast Industrial Road
Branford, Connecticut 06405

Re: Registration St ate ment on Form S-8 relating to the Issuance of Shares of Common Stock
Pursuant to the Amended and Restated Neurogen Corporation 2001 Stock Option Plan

Ladies and Gentlemen:

We have acted as counsel to Neurogen Corporation, a Delaware corporation (the “Company”), in connection with the preparation of a registration statement on Form S-8 (the “Registration Statement”) to be filed with the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended (the “Act”), relating to the offering of up to 1,500,000 shares of the Company’s Common Stock, par value $.025 per share (the “Shares”), to be issued pursuant to the provisions of the Amended and Restated Neurogen Corporation 2001 Stock Option Plan. We have examined such records, documents, statutes and decisions as we have deemed relevant in rendering this opinion.

We are of the opinion that when:

(a) the applicable provisions of the Act and of State securities or blue sky laws shall have been complied with;

(b) the Company’s Board of Directors shall have duly authorized the issuance of the Shares; and

(c) the Shares have been duly issued and paid for in an amount not less than par value of $.025 per share,
the Shares will be legally issued, fully paid and non-assessable.

We hereby consent to the use of this opinion as Exhibit 5.1 to the Registration Statement. In giving such opinion, we do not thereby admit that we are acting within the category of persons whose consent is required under Section 7 of the Act or the rules or regulations of the Commission thereunder.

  Very truly yours,
 


/s/ Milbank, Tweed , Hadley & McCloy LLP

 

 

-----END PRIVACY-ENHANCED MESSAGE-----